文献速递胸部肿瘤

基因组不稳定与促肿瘤炎症与恶性胸膜间皮瘤抗PD-1联合抗血管生成原发耐药相关

Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma.
PubMed 文献 · Cancer Discov · 2023-01-01

多中心PEMBIB试验(NCT02856425)纳入30例晚期恶性胸膜间皮瘤患者,接受帕博利珠单抗联合尼达尼布治疗。耐药患者经治疗后肿瘤通过CXCL9募集CD3+CD8+细胞毒性T细胞,但肿瘤体细胞拷贝数改变高,伴血与肿瘤IL6、CXCL8升高,促VEGF分泌及调节性T细胞富集。

要点

  • 耐药肿瘤并非缺乏T细胞浸润,而是经CXCL9释放主动募集CD3+CD8+细胞毒性T细胞。
  • 肿瘤体细胞拷贝数改变水平高与血和肿瘤中IL6、CXCL8水平高相关。
  • 上述促炎细胞因子使肿瘤VEGF分泌增多并富集调节性T细胞。

核心结论

  • 恶性胸膜间皮瘤对抗PD-1联合抗血管生成的原发耐药与肿瘤适应性免疫抑制通路相关,而非T细胞浸润不足。
  • 作者认为晚期间皮瘤应进一步从按肿瘤生物学分层的联合治疗中获益。

研究设计与样本

  • 多中心PEMBIB试验(NCT02856425),30例晚期恶性胸膜间皮瘤患者接受帕博利珠单抗联合尼达尼布治疗并接受探索。
  • 对新鲜肿瘤活检进行序贯探索。

主要发现

  • 意外发现难治患者经治疗后其肿瘤通过CXCL9释放主动募集CD3+CD8+细胞毒性T细胞。
  • 这些患者肿瘤体细胞拷贝数改变水平高,且与血液和肿瘤中IL6、CXCL8水平高相关。
  • 上述促炎细胞因子导致肿瘤VEGF分泌增多及肿瘤内调节性T细胞富集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Cancer immunotherapy combinations have recently been shown to improve the overall survival of advanced mesotheliomas, especially for patients responding to those treatments. We aimed to characterize the biological correlates of malignant pleural mesotheliomas' primary resistance to immunotherapy and antiangiogenics by testing the combination of pembrolizumab, an anti-PD-1 antibody, and nintedanib, a pan-antiangiogenic tyrosine kinase inhibitor, in the multicenter PEMBIB trial (NCT02856425). Thirty patients with advanced malignant pleural mesothelioma were treated and explored. Unexpectedly, we found that refractory patients were actively recruiting CD3+CD8+ cytotoxic T cells in their tumors through CXCL9 tumor release upon treatment. However, these patients displayed high levels of somatic copy-number alterations in their tumors that correlated with high blood and tumor levels of IL6 and CXCL8. Those proinflammatory cytokines resulted in higher tumor secretion of VEGF and tumor enrichment in regulatory T cells. Advanced mesothelioma should further benefit from stratified combination therapies adapted to their tumor biology. SIGNIFICANCE: Sequential explorations of fresh tumor biopsies demonstrated that mesothelioma resistance to anti-PD-1 + antiangiogenics is not due to a lack of tumor T-cell infiltration but rather due to adaptive immunosuppressive pathways by tumors, involving molecules (e.g., IL6, CXCL8, VEGF, and CTLA4) that are amenable to targeted therapies. This article is highlighted in the In This Issue feature, p. 799.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Danlos FX, Texier M, Job B, et al. Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma. Cancer Discov. 2023. PMID: 36669143. doi:10.1158/2159-8290.CD-22-0886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。